Transforming Healthcare through Advanced AI and Imaging Technologies: Quibim

Hospitals, real-world evidence specialists, research institutions, and biopharmaceutical businesses all have access to vast amounts of validated data that are critical to scientific progress. Partnering with Quibim allows for the extraction of significant, previously overlooked insights from large imaging data, as well as clinical and radiomic information acquired over years of activity and clinical research.

Quibim provides a comprehensive, all-in-one platform that acts as a centralized hub for handling, integrating, storing, and analyzing multi-omics data, with imaging at its core. The platform employs AI-powered solutions and data harmonization tools to ensure uniform image quality while minimizing variability among equipment manufacturers and acquisition processes. This all-encompassing platform streamlines drug development programs while also improving patient care. The key features include:

Robust Data Security: Using modern security methods, data is encrypted at rest and in flight, and the company is ISO 27001 certified.

Patient Data Privacy: The platform enables complete de-identification of patient data, ensuring compliance with privacy regulations.

Integration Capabilities: Integration with local PACS allows for automatic transfer of pictures and reports via QP-Link, streamlining workflows.

Real-Time Quality Control: The platform enables real-time data quality control and radiological measurements to ensure correctness.

Automated Biomarker Quantification: The company provides fully automated quantification of imaging biomarkers, which improves efficiency.

Structured Reporting: Customizable, structured quantitative reports are given directly to PACS to improve decision-making.

Quibim's platform enables stakeholders in the medical and research domains by providing not just data management but also a package of capabilities to improve the quality, efficiency, and compliance of imaging and multi-omics data use.

QP-Prostate^®: Transforming Prostate Cancer Diagnosis

QP-Prostate^®, an innovative solution in prostate MRI utilizing Artificial Intelligence. This advanced system offers automated prostate segmentation and lesion detection, with the distinction of being CE, UKCA mark, and FDA 510(k) cleared. It's important to note that the lesion detection functionality is currently under clinical investigation and not available for sale.

In the landscape of men's health, where prostate cancer stands as the second most prevalent cancer, QP-Prostate emerges as a game-changer. With MRI scans playing a crucial role in early detection, the surge in demand has outpaced the growth of radiology experts, leading to diagnostic delays and inconsistent interpretations, notably in adherence to PI-RADS 2.1 guidelines.

QP-Prostate steps in as an AI-powered solution, meticulously designed to streamline radiologists' workflows. By autonomously assessing image quality, segmenting the prostate gland, and identifying suspicious lesions*, QP-Prostate empowers radiologists to provide quicker and more precise assessments. This not only addresses the challenges posed by the growing demand for scans but also contributes to more efficient and accurate patient care.

QP-Brain^®: Revolutionizing Brain MRI Analysis

QP-Brain^®, a groundbreaking AI-based software designed for the early-stage quantification of neurological diseases. This innovative solution specializes in quantifying early brain atrophy and lesions, holding authorization for use in the US, EU, and UK.

In an era marked by an aging population and a rising prevalence of neurodegenerative diseases, there exists an imperative for more accurate assessments to detect early changes in brain structures, white matter hyperintensities (WMH) load, and their locations. QP-Brain^® steps in as an AI-powered tool that reshapes the landscape of brain MRI analysis, offering quantitative evaluations for improved detection and a deeper understanding of brain atrophy and lesions.

This advanced software automates the quantitative analysis of patients' brain imaging, consolidating crucial data on brain structure volumes and WMH load/location. This not only aids in diagnostics but also facilitates follow-up assessments. Furthermore, QP-Brain^® plays a pivotal role in enhancing the efficiency of radiological reporting by providing clear and communicative quantitative analyses of patients' brains. In essence, QP-Brain^® stands as a transformative solution at the forefront of neurological disease quantification, contributing to early detection and improved patient care.

QP-Liver: MRI-Based Automated Liver Segmentation

Quibim takes a significant leap forward in advancing the diagnosis of diffuse liver diseases by introducing a groundbreaking product focused on highly accurate quantification of tissue fat and iron through MRI. This innovative solution not only marks a pivotal development in medical imaging but also showcases the integration of state-of-the-art AI models for automated liver segmentation, ensuring unparalleled precision in diagnostic capabilities.

The core strength of this new product lies in its ability to leverage the most advanced AI models, which excel in accuracy and efficiency, to automate the intricate process of liver segmentation. This entails precisely identifying and delineating liver structures from MRI scans, providing clinicians with a detailed and accurate representation of the organ for diagnostic purposes.

A noteworthy aspect of this product is its validation against digital pathology, signifying a robust and reliable methodology. By aligning the AI-driven liver segmentation results with the gold standard of digital pathology, Quibim ensures that its technology meets rigorous standards and provides results that can be trusted by healthcare professionals.

This integration of AI-driven automated liver segmentation not only enhances the accuracy of quantifying tissue fat and iron but also streamlines and expedites the diagnostic process. Clinicians can now rely on a technology that not only keeps pace with the evolving landscape of medical imaging but also sets new standards in precision, contributing significantly to the improvement of diagnoses for diffuse liver diseases.

Ángel Alberich-Bayarri | Co-Founder & CEO

“Our all-in-one solution provides data privacy, a safe and continuously available platform, and ensures safe communication back and forth between your institution and the Quibim cloud.”